
Chordate’s study results published in Neurology
Chordate Medical’s results from the migraine study PM007 with Ozilia have now been published in the highly ranked journal Neurology. The publication has been eagerly awaited by both shareholders and other stakeholders, leading to a stock price increase of over 90 percent. According to CEO Anders Weilandt, the scientific article will play a central role in the company’s ongoing marketing strategy and exit process.
Chordate Medical is a medtech company that has developed Ozilia, a drug-free treatment technology for chronic migraine and chronic rhinitis.
Between 2018 and 2022, the company conducted a large patient study (PM007) aimed at evaluating the efficacy and safety of the treatment in patients with chronic migraine. A total of 132 patients were recruited, with half receiving active treatment and the other half receiving a placebo.
In summary, the study results demonstrated that the treatment provides significant benefits for patients with chronic migraine by reducing the number of headache and migraine days per month, as well as the use of medication.
Benefits for patients with chronic migraine
A scientific article presenting the study results has now been published in the esteemed journal Neurology, following review and approval by an independent expert panel. You can read the article here.
The article reports that the Ozilia treatment reduced the number of monthly headache days by an average of 3.5 days during the four-week active treatment period and by 2.7 days during the four-week follow-up period. The number of migraine days also decreased during both the active treatment period and follow-up period.
The study further confirms that the treatment is safe and well-tolerated, as reflected in the low drop-out rate of participants. No treatment-related serious adverse events were observed.
The published article also highlights that the study population represents a complex patient group who have already tried many treatment options and often suffer from comorbidities such as depression and sleep disturbances.
CEO comments on the publication
The study results and publication in Neurology demonstrate that Ozilia is a valuable addition to the treatment arsenal and a strong alternative to drug-based migraine therapies, according to Chordate Medical’s CEO, Anders Weilandt:
– This publication confirms that the medical efficacy of the Ozilia treatment is on par with conventional drug-based alternatives for the preventive treatment of chronic migraine, a market estimated at approximately USD 8 billion in sales globally, with strong growth.

BioStock reached out to Anders to learn more about the significance of the publication in Neurology.
How significant will the publication be for Chordate Medical’s future work?
– It is absolutely crucial for the company’s overall value – and especially in the exit process – that we now have the evidence of Ozilia’s clinical efficacy published.
According to your press release, the study’s execution and results have received the highest classification, Class I. Can you explain what Class I classification means and why it is important for the credibility of the study’s results?
– Neurology grades the articles it publishes based on study and data quality, along with several other criteria. Achieving Class I means that readers can fully trust the findings presented in the article.
Which aspects of the published article do you want readers to pay special attention to?
– Firstly, the effect on reducing both the number of headache and migraine days. Secondly, the authors’ conclusion that Ozilia’s non-pharmacological nature positions it as a valuable addition to the current therapeutic portfolio for treating chronic migraine, particularly suitable for patients concerned about systemic side effects.
What has been the biggest challenge in conducting and publishing this study?
– The work on the manuscript and the process with Neurology has been handled by the authors and study leaders, primarily led by the principal investigator, Dr. Jan Hoffmann at King’s College, who has done an outstanding job. For our part, the main challenge has been maintaining patience during Neurology’s time-consuming review process. It is easy to lose hope, but the long-term goal of achieving a top-tier publication helped us persevere.
Finally, what are the next steps now that the article is published? How will Chordate Medical and your partners utilize the publication?
– Naturally, this significantly boosts our marketing and sales efforts in our focus markets and reimbursement discussions. Most importantly, the exit process gains an invaluable addition: a highly compelling argument for why it makes sense to invest in acquiring this asset.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.